Abrdn Life Sciences Investors Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Abrdn Life Sciences Investors.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Capital Markets earnings growth | 14.4% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
No updates
Recent updates
HQL: Hold Your Investments In This Healthcare CEF For Strong, Steady Yield
Sep 27HQL: 13% Discount Creates An Opportunity
Jun 29Tekla Life Sciences raises dividend by 6.5% to $0.33
Feb 15Tekla Life Sciences declines quarterly dividend by -11.4% to $0.31/share
Nov 16Tekla Life Sciences Investors: 10% Yield And Trading 10.5% Below NAV
Oct 23HQL: A Biotechnology Equity CEF With No Leverage
Jul 12HQL: Buy For The Yield, If You Can Stomach The Depreciation
Apr 27Tekla Life Sciences Investors: Buy For Steady, Quarterly Dividend
Feb 11Tekla Life Sciences Investors Rides Biotechnology Wave, Offers Growth With Steady Income
Sep 22Evaluating Closed-End Funds: HQL Is Another Fine Pick In A Hot Sector
Jun 29Tekla Life Sciences Investors: 8% Yield, 7% Discount
Jan 09Tekla Life Sciences declares $0.02 special dividend
Dec 21Tekla Life Sciences declares $0.40 dividend
Nov 16In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Abrdn Life Sciences Investors has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2023 | 4 | 5 | N/A | N/A | N/A |
| 12/31/2022 | 3 | -50 | N/A | N/A | N/A |
| 9/30/2022 | 3 | -105 | N/A | N/A | N/A |
| 6/30/2022 | 3 | -74 | N/A | N/A | N/A |
| 3/31/2022 | 3 | -43 | N/A | N/A | N/A |
| 12/31/2021 | 2 | 11 | N/A | N/A | N/A |
| 9/30/2021 | 2 | 65 | N/A | N/A | N/A |
| 6/30/2021 | 2 | 94 | N/A | N/A | N/A |
| 3/31/2021 | 2 | 124 | N/A | N/A | N/A |
| 12/31/2020 | 3 | 124 | N/A | N/A | N/A |
| 9/30/2020 | 3 | 123 | N/A | N/A | N/A |
| 6/30/2020 | 3 | 61 | N/A | N/A | N/A |
| 3/31/2020 | 3 | -1 | N/A | N/A | N/A |
| 12/31/2019 | 3 | -36 | N/A | N/A | N/A |
| 9/30/2019 | 2 | -70 | N/A | N/A | N/A |
| 6/30/2019 | 2 | -31 | N/A | N/A | N/A |
| 3/31/2019 | 2 | 9 | N/A | N/A | N/A |
| 12/31/2018 | 2 | 19 | N/A | N/A | N/A |
| 9/30/2018 | 2 | 29 | N/A | N/A | N/A |
| 6/30/2018 | 2 | 25 | N/A | N/A | N/A |
| 3/31/2018 | 2 | 22 | N/A | N/A | N/A |
| 12/31/2017 | 2 | 45 | N/A | N/A | N/A |
| 9/30/2017 | 2 | 69 | N/A | N/A | N/A |
| 6/30/2017 | 2 | 76 | N/A | N/A | N/A |
| 3/31/2017 | 2 | 84 | N/A | N/A | N/A |
| 12/31/2016 | 1 | 36 | N/A | N/A | N/A |
| 9/30/2016 | 1 | -12 | N/A | N/A | N/A |
| 6/30/2016 | 1 | -66 | N/A | N/A | N/A |
| 3/31/2016 | 2 | -120 | N/A | N/A | N/A |
| 12/31/2015 | 1 | -40 | N/A | N/A | N/A |
| 9/30/2015 | 1 | 40 | N/A | N/A | N/A |
| 6/30/2015 | 1 | 93 | N/A | N/A | N/A |
| 3/31/2015 | 1 | 145 | N/A | -13 | N/A |
| 12/31/2014 | 1 | 117 | N/A | -33 | N/A |
| 9/30/2014 | 1 | 89 | N/A | -53 | N/A |
| 6/30/2014 | 1 | 92 | N/A | -21 | N/A |
| 3/31/2014 | 1 | 94 | N/A | 11 | N/A |
| 12/31/2013 | 1 | 89 | N/A | 10 | N/A |
| 9/30/2013 | 1 | 85 | N/A | 9 | N/A |
| 6/30/2013 | 1 | 67 | N/A | 9 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if HQL's forecast earnings growth is above the savings rate (2.4%).
Earnings vs Market: Insufficient data to determine if HQL's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if HQL's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if HQL's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if HQL's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if HQL's Return on Equity is forecast to be high in 3 years time